What is a stock summary page? Click here for an overview.
Business Description
HLS Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA40390B1094
Compare
Compare
Traded in other countries / regions
HLS.CanadaHLTRF.USA74D.Germany IPO Date
2010-01-27Description
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.26 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.93 | |||||
| Debt-to-EBITDA | 3.98 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -0.66 | |||||
| Beneish M-Score | -3.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2 | |||||
| 3-Year EBITDA Growth Rate | -8.7 | |||||
| 3-Year EPS without NRI Growth Rate | -13.5 | |||||
| 3-Year FCF Growth Rate | -9 | |||||
| 3-Year Book Growth Rate | -20.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 37.98 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.21 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 83.32 | |||||
| 9-Day RSI | 77.77 | |||||
| 14-Day RSI | 74.34 | |||||
| 3-1 Month Momentum % | 5.82 | |||||
| 6-1 Month Momentum % | 7.78 | |||||
| 12-1 Month Momentum % | -6.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.57 | |||||
| Quick Ratio | 1.17 | |||||
| Cash Ratio | 0.77 | |||||
| Days Inventory | 363.55 | |||||
| Days Sales Outstanding | 54.6 | |||||
| Days Payable | 495.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.7 | |||||
| Shareholder Yield % | 13.9 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.09 | |||||
| Operating Margin % | -19.49 | |||||
| Net Margin % | -34.51 | |||||
| FCF Margin % | 14.13 | |||||
| ROE % | -23.45 | |||||
| ROA % | -10.59 | |||||
| ROIC % | -8.98 | |||||
| 3-Year ROIIC % | 4 | |||||
| ROC (Joel Greenblatt) % | -622.04 | |||||
| ROCE % | -3.4 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.92 | |||||
| PB Ratio | 1.48 | |||||
| Price-to-Free-Cash-Flow | 13.51 | |||||
| Price-to-Operating-Cash-Flow | 13.51 | |||||
| EV-to-EBIT | -27.52 | |||||
| EV-to-EBITDA | 8.79 | |||||
| EV-to-Revenue | 2.67 | |||||
| EV-to-Forward-Revenue | 2.58 | |||||
| EV-to-FCF | 19.66 | |||||
| Price-to-GF-Value | 1.03 | |||||
| Price-to-Projected-FCF | 1.08 | |||||
| Earnings Yield (Greenblatt) % | -3.63 | |||||
| FCF Yield % | 7.82 | |||||
| Forward Rate of Return (Yacktman) % | -7.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HLTRF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HLS Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 56.619 | ||
| EPS (TTM) ($) | -0.62 | ||
| Beta | 0.49 | ||
| 3-Year Sharpe Ratio | -0.55 | ||
| 3-Year Sortino Ratio | -0.74 | ||
| Volatility % | 38.71 | ||
| 14-Day RSI | 74.34 | ||
| 14-Day ATR ($) | 0.043005 | ||
| 20-Day SMA ($) | 3.026875 | ||
| 12-1 Month Momentum % | -6.46 | ||
| 52-Week Range ($) | 2.22 - 4 | ||
| Shares Outstanding (Mil) | 31.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HLS Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HLS Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
HLS Therapeutics Inc Frequently Asked Questions
What is HLS Therapeutics Inc(HLTRF)'s stock price today?
The current price of HLTRF is $3.29. The 52 week high of HLTRF is $4.00 and 52 week low is $2.22.
When is next earnings date of HLS Therapeutics Inc(HLTRF)?
The next earnings date of HLS Therapeutics Inc(HLTRF) is 2025-05-09 Est..
Does HLS Therapeutics Inc(HLTRF) pay dividends? If so, how much?
HLS Therapeutics Inc(HLTRF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers